These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38551680)

  • 1. Origin and significance of leucine-rich glioma-inactivated 1 antibodies in cerebrospinal fluid.
    Zhang F; Zhou H; Yi Y; Li N; Liu M; Shen H; Guo Y; Wang J
    Neurol Sci; 2024 Sep; 45(9):4493-4500. PubMed ID: 38551680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis.
    Muñiz-Castrillo S; Haesebaert J; Thomas L; Vogrig A; Pinto AL; Picard G; Blanc C; Do LD; Joubert B; Berzero G; Psimaras D; Alentorn A; Rogemond V; Dubois V; Ambati A; Tamouza R; Mignot E; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33848259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal B-cell activation in LGI1 antibody encephalitis.
    Lehmann-Horn K; Irani SR; Wang S; Palanichamy A; Jahn S; Greenfield AL; Dandekar R; Lepennetier G; Michael S; Gelfand JM; Geschwind MD; Wilson MR; Zamvil SS; von Büdingen HC
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 32029531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum and CSF cytokine levels mirror different neuroimmunological mechanisms in patients with LGI1 and Caspr2 encephalitis.
    Körtvelyessy P; Goihl A; Guttek K; Schraven B; Prüss H; Reinhold D
    Cytokine; 2020 Nov; 135():155226. PubMed ID: 32799011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis.
    Dürr M; Nissen G; Sühs KW; Schwenkenbecher P; Geis C; Ringelstein M; Hartung HP; Friese MA; Kaufmann M; Malter MP; Madlener M; Thaler FS; Kümpfel T; Senel M; Häusler MG; Schneider H; Bergh FT; Kellinghaus C; Zettl UK; Wandinger KP; Melzer N; Gross CC; Lange P; Dreyhaupt J; Tumani H; Leypoldt F; Lewerenz J;
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34697224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHI3L1 in the CSF is a potential biomarker for anti-leucine-rich glioma inactivated 1 encephalitis.
    Li J; Li H; Wang Y; Zhao X; Wang S; Li L
    Front Immunol; 2022; 13():1071219. PubMed ID: 36685530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive LGI1 Antibodies in CSF and Relapse Relate to Worse Outcome in Anti-LGI1 Encephalitis.
    Cui LL; Boltze J; Zhang Y
    Front Immunol; 2021; 12():772096. PubMed ID: 34975858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of 28 cases of anti
    Feng J; Li J; Xie Y; Lü Y; Bi F; Zhou J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):386-396. PubMed ID: 37164922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LGI1 encephalitis: potentially complement-activating anti-LGI1-IgG subclasses 1/2/3 are associated with the development of hippocampal sclerosis.
    Bien CG; Rada A; Mertens M; Bien CI; Bauer J; Hagemann A; Woermann FG
    J Neurol; 2024 Sep; 271(9):6325-6335. PubMed ID: 39105896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study.
    Muñoz-Lopetegi A; Guasp M; Prades L; Martínez-Hernández E; Rosa-Justícia M; Patricio V; Armangué T; Rami L; Borràs R; Castro-Fornieles J; Compte A; Gaig C; Santamaria J; Dalmau J;
    Lancet Neurol; 2024 Mar; 23(3):256-266. PubMed ID: 38365378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Cerebrospinal Fluid Monoclonal LGI1 Autoantibodies Increase Neuronal Excitability.
    Kornau HC; Kreye J; Stumpf A; Fukata Y; Parthier D; Sammons RP; Imbrosci B; Kurpjuweit S; Kowski AB; Fukata M; Prüss H; Schmitz D
    Ann Neurol; 2020 Mar; 87(3):405-418. PubMed ID: 31900946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of patients with anti-leucine-rich glioma inactivated-1 protein associated encephalitis: a Chinese case series.
    Yang X; Li AN; Zhao XH; Liu XW; Wang SJ
    Int J Neurosci; 2019 Aug; 129(8):754-761. PubMed ID: 30621547
    [No Abstract]   [Full Text] [Related]  

  • 13. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study.
    Celicanin M; Blaabjerg M; Maersk-Moller C; Beniczky S; Marner L; Thomsen C; Bach FW; Kondziella D; Andersen H; Somnier F; Illes Z; Pinborg LH
    Eur J Neurol; 2017 Aug; 24(8):999-1005. PubMed ID: 28544133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of nine cases of leucine-rich glioma inactivated 1 protein antibody-associated encephalitis.
    Li Y; Song F; Liu W; Wang Y
    Acta Neurol Belg; 2021 Aug; 121(4):889-897. PubMed ID: 32232701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinction between anti-VGKC-complex seropositive patients with and without anti-LGI1/CASPR2 antibodies.
    Yeo T; Chen Z; Yong KP; Wong PYW; Chai JYH; Tan K
    J Neurol Sci; 2018 Aug; 391():64-71. PubMed ID: 30103974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features and outcomes in relapsing and monophasic patients with anti-leucine-rich glioma-inactivated 1 encephalitis].
    Li JM; Ma XR; Peng T; Li JH; Lu H
    Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1947-1951. PubMed ID: 32629594
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity.
    Malter MP; Frisch C; Schoene-Bake JC; Helmstaedter C; Wandinger KP; Stoecker W; Urbach H; Surges R; Elger CE; Vincent AV; Bien CG
    J Neurol; 2014 Sep; 261(9):1695-705. PubMed ID: 24935858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.
    Bien CG; Bien CI; Dogan Onugoren M; De Simoni D; Eigler V; Haensch CA; Holtkamp M; Ismail FS; Kurthen M; Melzer N; Mayer K; von Podewils F; Rauschka H; Rossetti AO; Schäbitz WR; Simova O; Witt K; Höftberger R; May TW
    J Neurol; 2020 Jul; 267(7):2101-2114. PubMed ID: 32246252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2.
    Murayama A; Sugaya K; Hara M; Kawazoe T; Tobisawa S; Nakajima H; Takahashi K
    Intern Med; 2023 Jun; 62(11):1659-1663. PubMed ID: 36223927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-brain metabolic pattern analysis in patients with anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.
    Mo J; Dong W; Cui T; Chen C; Shi W; Hu W; Zhang C; Wang X; Zhang K; Shao X
    Eur J Neurol; 2022 Aug; 29(8):2376-2385. PubMed ID: 35514068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.